The study involves testing epcoritamab, administered subcutaneously, in combination with oral and intravenous anti-neoplastic agents. These include drugs like lenalidomide, ibrutinib, and polatuzumab ...

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral treatment for a type of hereditary swelling disorder, sending its shares ...

William Blair analysts project AbbVie to earn $16.15 per share by FY2028, a notable jump from its current $12.31 estimate.

AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

AbbVie is testing its oral drug upadacitinib in a Phase 3 trial for patients with hidradenitis suppurativa (HS) who failed ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

W. Timothy Garvey, M.D., served as lead author in the clinical trial. A new combination drug therapy is showing extraordinary promise in the bout against obesity, helping patients lose an average of ...

Prime’s study analyzed pharmacy and medical claims data from its pool of 16.5 million commercially insured members to understand adherence and persistence to GLP-1 obesity medications over time.

AbbVie, in collaboration with Roche-Genentech, is conducting a Phase 3 clinical study titled ‘Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients With ...

NEW STUDY IDENTIFIES ADDITIONAL LINKS BETWEEN POULTRY ANTIBIOTIC USE AND HUMAN DRUG RESISTANCE Provided by GlobeNewswire Jun 25, 2025, 4:22:58 AM ...

AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the company published its Phase 3 TEMPLE study results, which were positive.